- Home
- XERS vs KALV Comparison
XERS vs KALV Comparison
Compare XERS & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | KALV |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XERS | KALV |
|---|---|---|
| Price | $6.01 | $26.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $10.83 | ★ $32.60 |
| AVG Volume (30 Days) | 1.6M | ★ 5.0M |
| Earning Date | 05-07-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $49,590,000.00 | ★ $50,000,000.00 |
| Revenue This Year | $34.37 | $185.42 |
| Revenue Next Year | $22.86 | $59.23 |
| P/E Ratio | $626.50 | ★ N/A |
| Revenue Growth | 142.67 | ★ 495.66 |
| 52 Week Low | $4.30 | $9.83 |
| 52 Week High | $10.08 | $26.85 |
Technical Indicators
Market Signals| Indicator | XERS | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 74.87 |
| Support Level | $5.79 | $14.45 |
| Resistance Level | $7.14 | N/A |
| Average True Range (ATR) | 0.30 | 0.07 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 4.33 | 54.55 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.